Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ReShape Lifesciences Inc (RSLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: RSLS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.54% | Avg. Invested days 69 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.68M USD | Price to earnings Ratio 0.01 | 1Y Target Price 1 |
Price to earnings Ratio 0.01 | 1Y Target Price 1 | ||
Volume (30-day avg) 1 | Beta 1.94 | 52 Weeks Range 2.23 - 348.00 | Updated Date 07/11/2025 |
52 Weeks Range 2.23 - 348.00 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 264.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -48.26% | Operating Margin (TTM) -165.23% |
Management Effectiveness
Return on Assets (TTM) -53.5% | Return on Equity (TTM) -120.16% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value 3436742 | Price to Sales(TTM) 0.79 |
Enterprise Value 3436742 | Price to Sales(TTM) 0.79 | ||
Enterprise Value to Revenue 0.48 | Enterprise Value to EBITDA -0.02 | Shares Outstanding 2385960 | Shares Floating 737812 |
Shares Outstanding 2385960 | Shares Floating 737812 | ||
Percent Insiders 10.63 | Percent Institutions 0.73 |
Upturn AI SWOT
ReShape Lifesciences Inc
Company Overview
History and Background
ReShape Lifesciences Inc., formerly known as EnteroMedics, was founded in 2002. Initially focused on neuromodulation for weight loss, the company transitioned to gastric balloon technology. Key milestones include FDA approvals and commercial launches of its products. The company has evolved its strategies and product offerings over the years.
Core Business Areas
- Gastric Balloon Technology: ReShape Lifesciences Inc. develops and commercializes medical devices used in the treatment of obesity. Its main product line features intragastric balloons that help patients lose weight by occupying space in the stomach, promoting satiety, and reducing food intake.
- ReShapeCare Virtual Weight Management Program: This program provides virtual support to patients undergoing weight loss procedures, including counseling, diet plans, and exercise guidance.
Leadership and Structure
The company is led by a management team with expertise in medical devices and the treatment of obesity. The organizational structure includes departments for research and development, sales and marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- ReShape Balloon: The ReShape Balloon is a dual intragastric balloon system designed to facilitate weight loss. Competitors include Apollo Endosurgery (NYSE: APEN) (now Boston Scientific), and Medtronic (MDT) with their respective intragastric balloon offerings. Limited market share data is available publicly. The company previously reported revenue from this product but has undergone restructuring.
- ReShapeCare: A virtual weight management program designed to support patients using ReShape's weight loss devices or other weight management solutions. This provides ongoing guidance and support through lifestyle changes. Competitors include various telehealth weight management programs offered by companies like WW International (WW) and Ro.
Market Dynamics
Industry Overview
The obesity treatment market includes lifestyle changes, medical devices, pharmaceuticals, and surgical procedures. The market is driven by the increasing prevalence of obesity and related health conditions.
Positioning
ReShape Lifesciences Inc. focuses on providing less-invasive alternatives to bariatric surgery through its gastric balloon technology and virtual weight management programs. Its competitive advantage lies in its proprietary technologies and patient support programs.
Total Addressable Market (TAM)
The global obesity management market is projected to reach hundreds of billions of dollars. ReShape is positioned within the medical device and virtual care segments, with the potential to capture a portion of this large market through its innovative solutions.
Upturn SWOT Analysis
Strengths
- Innovative gastric balloon technology
- ReShapeCare virtual weight management program
- Focus on less-invasive obesity treatment options
- Experienced management team in medical devices
- Intellectual property protection
Weaknesses
- Limited market share compared to larger competitors
- Financial instability
- Historical losses
- High operating costs
- Reliance on regulatory approvals for new products
Opportunities
- Expanding the product line to include additional weight management solutions
- Partnerships with healthcare providers and insurers
- Geographic expansion into new markets
- Increasing awareness of less-invasive obesity treatments
- Further development of ReShapeCare platform
Threats
- Competition from established medical device companies
- Regulatory hurdles and changing reimbursement policies
- Adverse clinical trial results
- Economic downturn impacting consumer spending on elective procedures
- Technological advancements that could render existing products obsolete
Competitors and Market Share
Key Competitors
- MDT
- BSX
- WW
Competitive Landscape
ReShape Lifesciences Inc. faces intense competition from larger, more established medical device companies. It differentiates itself through its focus on less-invasive procedures and patient support programs. However, its limited financial resources pose a challenge.
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth has been inconsistent, with periods of rapid growth followed by declines due to various factors, including market conditions and regulatory challenges.
Future Projections: Future growth projections are uncertain and depend on the successful commercialization of new products and the expansion of the ReShapeCare program. Analyst estimates are not widely available due to the company's small market capitalization.
Recent Initiatives: Recent initiatives include focusing on expanding the reach of ReShapeCare and strategic partnerships to broaden their market presence.
Summary
ReShape Lifesciences is a small player in the obesity treatment market with innovative technology. However, its financial instability, limited market share, and dependence on regulatory approvals pose significant challenges. Success hinges on successful commercialization efforts and effective management of resources, especially in the face of strong competitors. ReshapeLifesciences must look to capitalize on the growing market for weight loss solutions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Press releases
- Third-party financial data providers
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ReShape Lifesciences Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2007-11-15 | CEO, President & Director Mr. Paul F. Hickey | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17 | |
Full time employees 17 | |||
ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.